Loading institutional data...
Loading institutional data...
Held by 974 of 5,944 reporting institutions (99th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Ranked against 1111 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | $1.05T | 51.0× | — | 16.1× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $679.0B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $620.1B | 23.4× | — | 6.6× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $435.4B | 104.3× | 31.4× | 7.1× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| UNH | $374.0B | 31.2× | 21.4× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| BDRX | $359.1B | — | — | — | — | — | — | — | — | — | 7 |
| MRK | $321.1B | 17.6× | — | 4.9× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| NVSEF | $289.9B | — | — | — | — | — | — | — | — | — | 2 |
| AZN | $250.4B | — | — | — | — | — | — | — | — | — | 1,248 |
| AMGN | $219.7B | 28.7× | 18.3× | 6.0× | 10.0% | 67.2% | 21.0% | 89.1% | 13.1% | 3.5× | 3,014 |
| TMO | $217.8B | 32.6× | 28.5× | 4.9× | 3.9% | — | 15.1% | 12.6% | 7.0% | 4.9× | 2,481 |
| ABT | $183.9B | 28.4× | 19.5× | 4.2× | 5.7% | 56.4% | 14.7% | 12.5% | 10.5% | 1.0× | 2,964 |
| GILD | $163.5B | 19.4× | 18.1× | 5.5× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| PFE | $146.7B | 19.0× | — | 2.3× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $141.1B | 39.5× | 29.3× | 5.7× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $133.2B | 47.7× | 36.6× | 13.2× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| SYK | $128.8B | 40.1× | 21.8× | 5.1× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| CVS | $126.0B | 71.3× | 12.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| VRTX | $123.1B | 31.6× | 26.9× | 10.3× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| MDT | $110.1B | 23.1× | 11.7× | 3.0× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| GLAXF | $106.9B | — | — | — | — | — | — | — | — | — | 5 |
| MCK | $102.7B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| SNYNF | $101.3B | — | — | — | — | — | — | — | — | — | 5 |
| HCA | $92.0B | 14.5× | — | 1.2× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $86.4B | 15.5× | 14.8× | 0.4× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| VEEV | $35.0B | 39.3× | — | 10.9× | 16.3% | 75.5% | 28.4% | 12.6% | 12.6% | — | 974 |
Peers = companies sharing VEEV's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
6/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $170M buybacks = $170M returned.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 13%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest expense isn't separately reported — often netted into “other income (expense), net.”
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-08-05
No material risks flagged.
Is the profit real, and how strong is the balance sheet?
FY2026 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 2.0× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 28.4 | 27.5 | 27.9 | 27.2 | 28.3 | 28.7 | 25.5 | 24.5 |
| Gross Profit | 71.6 | 72.5 | 72.1 | 72.8 | 71.7 | 71.3 | 74.5 | 75.5 |
| R&D | 18.4 | 19.0 | 20.1 | 20.6 | 24.1 | 26.6 | 25.2 | 24.0 |
| SG&A | 10.0 | 10.3 | 10.2 | 9.3 | 10.1 | 10.4 | 9.7 | 9.4 |
| Operating Income | 25.8 | 25.9 | 25.8 | 27.3 | 21.3 | 18.2 | 25.2 | 28.7 |
| Income Tax | 1.0 | 1.1 | 1.0 | 4.6 | 1.0 | 2.6 | 7.5 | 8.9 |
| Net Income | 26.7 | 27.3 | 25.9 | 23.1 | 22.6 | 22.2 | 26.0 | 28.4 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on VEEV: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-08-05 · 15d old
How a revenue dollar becomes profit — FY2026
Each value shows its share of revenue below it (common-size).
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.20B 100.0% | $2.75B 100.0% | $2.36B 100.0% | $2.16B 100.0% | $1.85B 100.0% | $1.47B 100.0% | $1.10B 100.0% | $862.2M 100.0% | $690.6M 100.0% | $550.5M 100.0% |
| Cost of Revenue | $782.0M 24.5% | $699.6M 25.5% | $677.3M 28.7% | $609.4M 28.3% | $503.7M 27.2% | $408.9M 27.9% | $303.4M 27.5% | $245.3M 28.4% | $211.4M 30.6% | $173.7M 31.5% |
| Gross Profit | $2.41B 75.5% | $2.05B 74.5% | $1.69B 71.3% | $1.55B 71.7% | $1.35B 72.8% | $1.06B 72.1% | $800.7M 72.5% | $616.9M 71.6% | $479.1M 69.4% | $376.9M 68.5% |
| Research & Development | $767.4M 24.0% | $693.1M 25.2% | $629.0M 26.6% | $520.3M 24.1% | $382.0M 20.6% | $294.2M 20.1% | $209.9M 19.0% | $158.8M 18.4% | $132.0M 19.1% | $96.7M 17.6% |
| Selling, General & Admin | $300.7M 9.4% | $265.7M 9.7% | $246.5M 10.4% | $217.6M 10.1% | $171.5M 9.3% | $149.1M 10.2% | $114.3M 10.3% | $86.4M 10.0% | $60.4M 8.7% | $48.8M 8.9% |
| Total Operating Expenses | $1.50B 46.8% | $1.36B 49.4% | $1.26B 53.2% | $1.09B 50.4% | $841.6M 45.5% | $678.3M 46.3% | $514.5M 46.6% | $394.1M 45.7% | $321.2M 46.5% | $256.2M 46.5% |
| Operating Income | $916.4M 28.7% | $691.4M 25.2% | $429.3M 18.2% | $459.1M 21.3% | $505.5M 27.3% | $377.8M 25.8% | $286.2M 25.9% | $222.9M 25.8% | $157.9M 22.9% | $120.7M 21.9% |
| Other Income (Expense), net | $278.1M 8.7% | $227.9M 8.3% | $158.7M 6.7% | $50.0M 2.3% | $6.8M 0.4% | $16.2M 1.1% | $27.5M 2.5% | $15.8M 1.8% | $7.8M 1.1% | $1.7M 0.3% |
| Pretax Income | $1.19B 37.4% | $919.4M 33.5% | $588.0M 24.9% | $509.1M 23.6% | $512.3M 27.7% | $394.0M 26.9% | $313.7M 28.4% | $238.6M 27.7% | $165.8M 24.0% | $122.4M 22.2% |
| Income Tax Expense | $285.6M 8.9% | $205.2M 7.5% | $62.3M 2.6% | $21.4M 1.0% | $84.9M 4.6% | $14.0M 1.0% | $12.6M 1.1% | $8.8M 1.0% | $14.6M 2.1% | $44.8M 8.1% |
| Net Income | $908.9M 28.4% | $714.1M 26.0% | $525.7M 22.2% | $487.7M 22.6% | $427.4M 23.1% | $380.0M 25.9% | $301.1M 27.3% | $229.8M 26.7% | $151.2M 21.9% | $77.6M 14.1% |
| Per Share | ||||||||||
| EPS (Basic) | $5.55 | $4.41 | $3.27 | $3.14 | $2.79 | $2.52 | $2.04 | $1.59 | $1.08 | $0.57 |
| EPS (Diluted) | $5.44 | $4.32 | $3.22 | $3.00 | $2.63 | $2.36 | $1.90 | $1.47 | $0.98 | $0.53 |
| Weighted Avg Shares (Basic) | 163.7M | 161.9M | 160.5M | 155.4M | 153.3M | 150.7M | 147.8M | 144.2M | 140.3M | 135.7M |
| Weighted Avg Shares (Diluted) | 167.0M | 165.2M | 163.5M | 162.4M | 162.3M | 160.7M | 158.3M | 156.1M | 153.7M | 147.6M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.